FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/An article focusing on the latest review of rosacea pathogenesis and its implications for peptide therapy could attract interest from dermatologists and researchers interested in inflammatory skin conditions.
研究ライブラリに戻る
cathelicidinsinflammasome complexes

An article focusing on the latest review of rosacea pathogenesis and its implications for peptide therapy could attract interest from dermatologists and researchers interested in inflammatory skin conditions.

May 16, 2026
Share

元の論文

Rosacea: Pathogenesis and Therapeutic Correlates.

Geng Ryan S Q et al.Journal of cutaneous medicine and surgery2024
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Unraveling Rosacea: Insights into Pathogenesis and Therapeutic Targets

Published: May 16, 2026 | Source: Journal of cutaneous medicine and surgery (2024) | Category: cathelicidins, inflammasome complexes

Overview

A recent review in the Journal of Cutaneous Medicine and Surgery provides a comprehensive analysis of rosacea's complex pathogenesis, highlighting the pivotal role of pro-inflammatory pathways involving cathelicidins and inflammasome complexes. This understanding could pave the way for more effective peptide-based therapies aimed at managing this chronic inflammatory condition.

Study Background

Rosacea is a common skin disorder characterized by persistent redness, visible blood vessels, bumps, and pimples primarily affecting the central face. Despite its prevalence, the exact cause of rosacea remains elusive, making it challenging to develop targeted treatments. Prior research has suggested that genetic predisposition, environmental factors, and immune system dysregulation are likely contributors to the development and progression of rosacea. However, a detailed understanding of the molecular mechanisms underlying these processes was lacking until now.

What the Research Found

The review by Geng et al. synthesizes existing knowledge on the pathogenesis of rosacea, emphasizing the critical role of pro-inflammatory pathways involving cathelicidins and inflammasome complexes. Cathelicidins are antimicrobial peptides that play a significant role in innate immunity; however, their dysregulation can lead to inflammation. Inflammasomes are multiprotein complexes that activate caspase-1, leading to the maturation of pro-inflammatory cytokines such as interleukin (IL)-1β and IL-18. The review highlights how these pathways interact with environmental triggers like UV radiation, heat, and certain foods, contributing to the varied clinical presentations of rosacea.

What This Means for Peptide Users

Understanding the role of cathelicidins and inflammasome complexes in rosacea pathogenesis could lead to more targeted peptide therapies. For instance, peptides that inhibit the activation of these pathways or modulate their activity might offer new avenues for treating symptoms effectively. While current treatments such as topical metronidazole and oral antibiotics have shown efficacy, they often come with side effects and do not address the underlying inflammatory mechanisms comprehensively.

Limitations and Caveats

As a review paper, this study does not present original experimental data but rather synthesizes existing literature. Therefore, its conclusions are limited by the availability and quality of previous studies. Additionally, while the proposed pathways provide a promising framework for understanding rosacea, further research is needed to validate these mechanisms in clinical settings.

How This Compares to Previous Research

Previous studies have also pointed towards an inflammatory basis for rosacea but lacked the detailed molecular insights provided by this review. The emphasis on cathelicidins and inflammasome complexes offers a more refined understanding of the disease's pathogenesis, aligning with recent advances in immunology and dermatology.

Our Analysis

PeptideVault views this review as an important step towards a deeper understanding of rosacea's underlying mechanisms. While it does not provide definitive answers, it sets the stage for future research that could lead to more effective therapeutic interventions. The identification of cathelicidins and inflammasome complexes as key players in rosacea pathogenesis opens up new possibilities for peptide-based therapies.

Key Takeaways

  • Pathogenesis Insights: Rosacea's development is linked to dysregulated pro-inflammatory pathways involving cathelicidins and inflammasome complexes.
  • Therapeutic Targets: Future treatments may focus on modulating these pathways, potentially offering more targeted relief from symptoms.
  • Further Research Needed: While promising, the proposed mechanisms require validation through clinical trials.

Original Source

Citation: Geng Ryan S Q, Bourkas Adrienn N, Mufti Asfandyar et al. (2024). Rosacea: Pathogenesis and Therapeutic Correlates.. Journal of cutaneous medicine and surgery. DOI: 10.1177/12034754241229365

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。